Back to top
more

Syndax Pharmaceuticals (SNDX)

(Delayed Data from NSDQ)

$19.00 USD

19.00
3,994,862

-0.04 (-0.21%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $18.95 -0.05 (-0.26%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (156 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Will ACADIA (ACAD) Pull Off a Surprise this Earnings Season?

by Zacks Equity Research

ACADIA Pharmaceuticals' (ACAD) Nuplazid is expected to maintain the growth trend, established since its launch, in the second quarter.

    Zacks Equity Research

    Repros (RPRX) Q2 Earnings: What's in Store for the Stock?

    by Zacks Equity Research

    Lack of revenues in Repros Therapeutics' (RPRX) product portfolio could be a concern. But the company's most advanced pipeline candidates -- enclomiphene and Proellex -- might better its results in Q2.

      Zacks Equity Research

      Can Ligand (LGND) Pull a Surprise This Earnings Season?

      by Zacks Equity Research

      Milestone payment on Baxdela's approval in the U.S. leveraging Ligand's (LGND) Captisol formulation technology and partnerships with leading healthcare companies, might drive the company in Q2.

        Zacks Equity Research

        GW Pharmaceuticals (GWPH) Q3 Earnings: What Lies in Store?

        by Zacks Equity Research

        Investors will likely be looking at GW Pharmaceuticals' (GWPH) progress with its anti-epileptic pipeline candidate, Epidiolex in its fiscal third-quarter results.

          Zacks Equity Research

          Can Mallinckrodt (MNK) Deliver a Beat this Earnings Season?

          by Zacks Equity Research

          Investor focus is likely to be on Mallinckrodt plc's (MNK) progress with its strategic acquisitions and pipeline updates.

            Zacks Equity Research

            What's in the Cards for Adverum (ADVM) this Earnings Season?

            by Zacks Equity Research

            Investors will be looking at Adverum's (ADVM) updates on progress of its various pipeline candidates.

              Zacks Equity Research

              What's in the Cards for Merrimack (MACK) in Q1 Earnings?

              by Zacks Equity Research

              Merrimack Pharmaceuticals, Inc. (MACK) is expected to report first-quarter 2017 results around May 1. Last quarter, Merrimack missed bottom line expectations

                Zacks Equity Research

                Intrexon (XON): Will the Stock Pull a Surprise in Q4 Earnings?

                by Zacks Equity Research

                Intrexon Corporation (XON) is scheduled to report fourth-quarter 2016 results on Mar 1, after the market closes.

                  Zacks Equity Research

                  Agenus (AGEN): What's Ahead for the Stock in Q4 Earnings?

                  by Zacks Equity Research

                  Agenus Inc. (AGEN) is expected to report fourth-quarter 2016 results during this month.

                    Zacks Equity Research

                    Puma Biotechnology (PBYI) Q4 Earnings: What's in the Cards?

                    by Zacks Equity Research

                    Puma Biotechnology, Inc. (PBYI) is expected to report fourth-quarter 2016 results next month. The company has a mixed earnings history.